What Happened

Viridian Therapeutics, Inc. secured FDA approval for Lumvoa (veligrotug-vvze), a monoclonal antibody targeting IGF-1R for thyroid eye disease (TED). The treatment involves five 45-minute IV infusions over 12 weeks, with phase 3 trials meeting all endpoints. Viridian announced an immediate U.S. commercial launch alongside a patient support program (ViridianCares).

Who Is Affected

TED patients (active or chronic) now have a second FDA-approved option beyond Amgen's Tepezza. Eyecare providers and infusion centers will need to evaluate protocols for Lumvoa's administration, particularly given its 29% reported incidence of menstrual disorders in female patients.

Market Impact

• Introduces direct competition to Amgen's Tepezza (2020 approval)
• First TED treatment demonstrating diplopia resolution in both active/chronic cases
• ViridianCares program may influence provider adoption through patient access support

What to Watch

Monitor Viridian's commercialization velocity and real-world adherence rates given the 5-infusion regimen. Amgen may respond with pricing or provider incentives to defend Tepezza's market position. Viridian's pipeline includes another IGF-1R candidate (H1 2027 BLA target).